Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Voyager Therapeutics ( (VYGR) ).
Voyager Therapeutics announced its participation in Citi’s 2025 Biopharma Back to School Conference, highlighting its strategic advancements in neurotherapeutics. The company aims to optimize the delivery of therapeutics to the central nervous system through its innovative platforms, and anticipates significant clinical milestones in the coming years. This announcement underscores Voyager’s commitment to advancing its pipeline and strengthening its industry position, supported by substantial non-dilutive funding and collaborations.
The most recent analyst rating on (VYGR) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.
Spark’s Take on VYGR Stock
According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.
Voyager Therapeutics’ overall stock score is primarily impacted by its financial performance challenges, including negative profitability and cash flow issues. The technical analysis provides some stability with neutral indicators, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call and corporate events data means these factors do not influence the score.
To see Spark’s full report on VYGR stock, click here.
More about Voyager Therapeutics
Voyager Therapeutics operates in the biopharmaceutical industry, focusing on the development of therapies for neurological diseases. The company leverages genetic approaches and innovative delivery platforms, such as its TRACER capsid discovery platform, to advance treatments for conditions with high unmet needs, including Alzheimer’s disease. Voyager collaborates with major partners like Novartis and Neurocrine, and has a robust pipeline of neurotherapeutic programs.
Average Trading Volume: 726,680
Technical Sentiment Signal: Sell
Current Market Cap: $186.4M
For detailed information about VYGR stock, go to TipRanks’ Stock Analysis page.